financetom
Business
financetom
/
Business
/
New York REIT Alexander's Q3 FFO rises to $2.91
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
New York REIT Alexander's Q3 FFO rises to $2.91
Nov 3, 2025 6:50 AM

Overview

* Alexander's Q3 revenue beats analyst expectations, reaching $53.4 mln

* Net income for Q3 was $6.0 mln, surpassing analyst estimates

* FFO per diluted share rose to $2.91 from $2.84 yr/yr

Result Drivers

* REVENUE DECLINE - Co beat analyst expectations despite a decrease in revenue compared to last year

* NET INCOME DECLINE - Net income for the quarter was $6.0 million, compared to $6.7 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $53.42 $51.60

Revenue mln mln (1

Analyst)

Q3 EPS $1.16

Q3 Net Beat $5.96 $4.30

Income mln mln (1

Analyst)

Q3 $14.92

Adjusted mln

FFO

Q3 $2.91

Adjusted

FFO Per

Share

Analyst Coverage

* The one available analyst rating on the shares is "sell"

* The average consensus recommendation for the commercial reits peer group is "buy."

* Wall Street's median 12-month price target for Alexander's Inc is $155.00, about 42.5% below its October 31 closing price of $220.93

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abbott beats quarterly profit estimates on strong medical device sales
Abbott beats quarterly profit estimates on strong medical device sales
Apr 17, 2024
April 17 (Reuters) - Abbott Laboratories ( ABT ) beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its forecast, as robust demand for medical procedures boosted sales of its devices, including its glucose-monitoring products. On an adjusted basis, the company reported first-quarter profit of 98 cents per share, compared with analysts' estimate of...
BRIEF-State Street Said To Explore Acquisition Of SocGen'S Custody Arm; SocGen Said To Be Seeking More Than €1 Billion For The Unit- Bloomberg News
BRIEF-State Street Said To Explore Acquisition Of SocGen'S Custody Arm; SocGen Said To Be Seeking More Than €1 Billion For The Unit- Bloomberg News
Apr 17, 2024
April 17 (Reuters) - * STATE STREET SAID TO EXPLORE ACQUISITION OF SOCGEN'S CUSTODY ARM; SOCGEN SAID TO BE SEEKING MORE THAN €1 BILLION FOR THE UNIT- BLOOMBERG NEWS Source text : [ID:https://tinyurl.com/yduve98z] Further company coverage: ...
BRIEF-Nature's Miracle Holding And Agrify Corp Agree To Merge
BRIEF-Nature's Miracle Holding And Agrify Corp Agree To Merge
Apr 17, 2024
April 17 (Reuters) - Agrify Corp ( AGFY ): * NATURE'S MIRACLE HOLDING INC. AND AGRIFY CORPORATION AGREE TO MERGE * NATURE'S MIRACLE HOLDING INC - AGRIFY WOULD BE EXPECTED TO RECEIVE ABOUT 0.45 OF A SHARE OF CO'S COMMON STOCK FOR EACH SHARE OF AGRIFY COMMON STOCK Source text for Eikon: Further company coverage: ...
BRIEF-Future Pak Confirms Proposal To Acquire Vanda Pharmaceuticals For $7.25 To $7.75 Per Share In Cash
BRIEF-Future Pak Confirms Proposal To Acquire Vanda Pharmaceuticals For $7.25 To $7.75 Per Share In Cash
Apr 17, 2024
April 17 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ): * FUTURE PAK CONFIRMS PROPOSAL TO ACQUIRE VANDA PHARMACEUTICALS FOR $7.25 TO $7.75 PER SHARE IN CASH * FUTURE PAK - PROPOSES TO ACQUIRE 100% OF ISSUED AND OUTSTANDING SHARES OF VANDA * FUTURE PAK LLC : WOULD NOT REQUIRE A FINANCING CONTINGENCY IN CONNECTION WITH A TRANSACTION * FUTURE...
Copyright 2023-2026 - www.financetom.com All Rights Reserved